AstraZeneca’s Imfinzi Clinches Late-Stage Victory in Aggressive Lung Cancer
Following disappointing Phase III results in less aggressive non-small cell lung cancer, AstraZeneca on Friday announced that Imfinzi improved progression-free and overall survival in patients with limited-stage small cell lung cancer.